Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic
In this podcast episode, listen to Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, discuss important new clinical trial data for endometrial and ovarian cancers presented at the virtual ESMO 2021 annual meeting.
Bernard Doger de Spéville, MD, PhD
Prof Isabelle Ray-Coquard, MD, PhD
Released: September 29, 2021

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:

  • Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  
  • A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapy
  • A preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
  • Quality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancer

Information on this Educational Activity

Faculty

Bernard Doger de Spéville, MD, PhD

Medical Oncology
START-Madrid, Early Phase Clinical Trials Unit
Hospital Fundación Jiménez Diaz
Madrid, Spain

Bernard Doger de Spéville, MD, PhD, has no relevant conflicts of interest to report.
Prof Isabelle Ray-Coquard, MD, PhD

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Prof Isabelle Ray-Coquard, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, Deciphera, GlaxoSmithKline, Mersana, MSD, and Roche.

Program Medium

This program has been made available online.

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Podcast with Dr. Nelson F. Sanchez on caring for transgender individuals, from the healthcare disparities they face to how HCPs can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: May 13, 2022

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Released: May 13, 2022

Commentary on immunotherapy in endometrial cancer with a focus on older patients, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: April 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings